We envision a better way.


Impel Pharmaceuticals strives to create life-changing innovative therapies for diseases with an unmet need

Discover More

What We Do

Impel Pharmaceuticals is focused on developing and providing transformative therapies for people suffering from diseases with high unmet medical needs through the pioneering of an optimized approach to drug delivery. We offer and develop treatments that pair the Company’s proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics. Trudhesa® (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) is now approved for the acute treatment of migraine with or without aura in adults. Trudhesa was previously known as INP104.

The upper nasal space is surrounded by a rich vasculature that has the potential for injection-like absorption, resulting in more rapid and consistent bioavailability and clinical response. While an ideal target for drug delivery, to date no technology has been able to consistently deliver drugs predictably and consistently to the upper nasal space.

Impel Pharmaceuticals is investigating utilizing its performance technology to deliver proven treatments for multiple neurological conditions with high unmet need.

Press Releases

Oral Presentation Showcases Early Ability to Predict Responders to Trudhesa New Analysis Suggest Patient-Reported Benefits of Long-Term Use with Trudhesa…

SEATTLE, June 08, 2022 (GLOBE NEWSWIRE) — Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for…

Trudhesa ® Continues Strong Launch Trajectory with Q1 2022 TRx Growth of 111% vs. Q4 2021 Planned initiation of INP105…


1 Data on File